Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells

Guo,Xin; Guo,Nan; Zhao,Jianwen; Cai,Yunlang

doi:10.3892/or.2017.5829

Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells

Authors:
- Xin Guo
- Nan Guo
- Jianwen Zhao
- Yunlang Cai
View Affiliations

Affiliations: Medical School, Southeast University, Nanjing, Jiangsu 210009, P.R. China, Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Gynaecology and Obstetrics, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu 210009, P.R. China
Published online on: July 18, 2017 https://doi.org/10.3892/or.2017.5829
Pages: 1442-1450
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The combination of nanocarriers and chemotherapy drugs can release the chemotherapy drugs to the tumor tissue, which can enhance the antitumor effect and reduce the adverse reactions at the same time. In this study, a co-delivery system based on hollow mesoporous silica nanoparticles (HMSN) was developed and characterized. We also investigated the in vitro effect of this system on CD117+CD44+A2780 cell line. HMSN was selected as the nanocarrier, with -COOH modified on the surface and doxorubicin (DOX), NVP-AEW 541 (NVP) loaded inside. IGF‑1R was chosen as the drug target, apoptosis rate and expression of cyclin B1, Bax, Bcl-xl, p-Akt were used to evaluate the antitumor effect of HMSN‑COOH@DOX fluorescence NVP. The HMSN co-delivery system was successfully synthesized with encapsulation efficiency of 37% (DOX) and 44% (NVP), and high PH-sensitive property was observed. The apoptosis rate of CD117+CD44+A2780 ovarian cancer stem-like cells treated by HMSN co-delivery system were almost 3 times higher than those of the free drugs group. The expression of Bax was significantly increased while Bcl-xl, and p-Akt reduced (P≤0.05). These data indicate that the co-delivery system demonstrated a high efficiency in promoting apoptosis in ovarian cancer stem-like cells by targeting IGF‑1R, but further study is still needed.

View Figures

View References

1	Beauchamp MC, Yasmeen A, Knafo A and Gotlieb WH: Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol. 2010:2570582010. View Article : Google Scholar : PubMed/NCBI
2	Mantia-Smaldone GM, Corr B and Chu CS: Immunotherapy in ovarian cancer. Hum Vaccin Immunother. 8:1179–1191. 2012. View Article : Google Scholar : PubMed/NCBI
3	Boccardi E, Philippart A, Juhasz-Bortuzzo JA, Beltrán AM, Novajra G, Vitale-Brovarone C, Spiecker E and Boccaccini AR: Uniform surface modification of 3D bioglass (^®)-based scaffolds with mesoporous silica particles (MCM-41) for enhancing drug delivery capability. Front Bioeng Biotechnol. 3:1772015. View Article : Google Scholar : PubMed/NCBI
4	Liu J, Luo Z, Zhang J, Luo T, Zhou J, Zhao X and Cai K: Hollow mesoporous silica nanoparticles facilitated drug delivery via cascade pH stimuli in tumor microenvironment for tumor therapy. Biomaterials. 83:51–65. 2016. View Article : Google Scholar : PubMed/NCBI
5	Li N, Huang C, Luan Y, Song A, Song Y and Garg S: Active targeting co-delivery system based on pH-sensitive methoxy-poly (ethylene glycol)2K-poly (ε-caprolactone)4K-poly (glutamic acid)1K for enhanced cancer therapy. J Colloid Interface Sci. 472:90–98. 2016. View Article : Google Scholar : PubMed/NCBI
6	Huang Y, Jiang Y, Wang H, Wang J, Shin MC, Byun Y, He H, Liang Y and Yang VC: Curb challenges of the ‘Trojan Horse’ approach: Smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev. 65:1299–1315. 2013. View Article : Google Scholar : PubMed/NCBI
7	Han L, Tang C and Yin C: Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA. Biomaterials. 60:42–52. 2015. View Article : Google Scholar : PubMed/NCBI
8	Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care. 29:1990–1991. 2006. View Article : Google Scholar : PubMed/NCBI
9	Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H and Yu H: IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors. 25:346–354. 2007. View Article : Google Scholar : PubMed/NCBI
10	Attias-Geva Z, Bentov I, Fishman A, Werner H and Bruchim I: Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines. Gynecol Oncol. 121:383–389. 2011. View Article : Google Scholar : PubMed/NCBI
11	Zhan Q, Wang C and Ngai S: Ovarian cancer stem cells: A new target for cancer therapy. BioMed Res Int. 2013:9168192013. View Article : Google Scholar : PubMed/NCBI
12	Burgos-Ojeda D, Rueda BR and Buckanovich RJ: Ovarian cancer stem cell markers: Prognostic and therapeutic implications. Cancer Lett. 322:1–7. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, et al: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 203:871–881. 2006. View Article : Google Scholar : PubMed/NCBI
14	Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10:942–949. 2004. View Article : Google Scholar : PubMed/NCBI
15	Trinchero A, Bonora S, Tinti A and Fini G: Spectroscopic behavior of copper complexes of nonsteroidal anti-inflammatory drugs. Biopolymers. 74:120–124. 2004. View Article : Google Scholar : PubMed/NCBI
16	Gallagher EJ and LeRoith D: The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab. 21:610–618. 2010. View Article : Google Scholar : PubMed/NCBI
17	Jun YW, Lee JH and Cheon J: Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed Engl. 47:5122–5135. 2008. View Article : Google Scholar : PubMed/NCBI
18	Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R and Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751–760. 2007. View Article : Google Scholar : PubMed/NCBI
19	Gullotti E and Yeo Y: Extracellularly activated nanocarriers: A new paradigm of tumor targeted drug delivery. Mol Pharm. 6:1041–1051. 2009. View Article : Google Scholar : PubMed/NCBI
20	Meng H, Xue M, Xia T, Ji Z, Tarn DY, Zink JI and Nel AE: Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano. 5:4131–4144. 2011. View Article : Google Scholar : PubMed/NCBI
21	Liu N, Han J, Zhang X, Yang Y, Liu Y, Wang Y and Wu G: pH-responsive zwitterionic polypeptide as a platform for anti-tumor drug delivery. Colloids Surf B Biointerfaces. 145:401–409. 2016. View Article : Google Scholar : PubMed/NCBI
22	Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang DH and Chen ZS: Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat. 27:14–29. 2016. View Article : Google Scholar : PubMed/NCBI
23	Wu Q, Yang Z, Nie Y, Shi Y and Fan D: Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
24	Whitley BR, Beaulieu LM, Carter JC and Church FC: Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol. 104:470–479. 2007. View Article : Google Scholar : PubMed/NCBI
25	Yang B, Zhao Y, Lou C and Zhao H: Eupalinolide O, a novel sesquiterpene lactone from Eupatorium lindleyanum DC., induces cell cycle arrest and apoptosis in human MDA-MB-468 breast cancer cells. Oncol Rep. 36:2807–2813. 2016.PubMed/NCBI
26	Wang LH, Jiang XR, Chen GL, Guo W, Zhang JY, Cui LJ, Li HH, Li M, Liu X, Yang JY, et al: Anti-tumor activity of SL4 against breast cancer cells: Induction of G2/M arrest through modulation of the MAPK-dependent p21 signaling pathway. Sci Rep. 6:364862016. View Article : Google Scholar : PubMed/NCBI
27	Subramaniam S and Unsicker K: Extracellular signal-regulated kinase as an inducer of non-apoptotic neuronal death. Neuroscience. 138:1055–1065. 2006. View Article : Google Scholar : PubMed/NCBI
28	Andersen JL and Kornbluth S: The tangled circuitry of metabolism and apoptosis. Mol Cell. 49:399–410. 2013. View Article : Google Scholar : PubMed/NCBI
29	Singh RK, Gaikwad SM, Jinager A, Chaudhury S, Maheshwari A and Ray P: IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. Cancer Lett. 354:254–262. 2014. View Article : Google Scholar : PubMed/NCBI
30	Jia J, Zhang Y, Cai J, Wang J, Ding H, Zhou J, Fang F and Wang Z: A novel function of protein kinase B as an inducer of the mismatch repair gene hPMS2 degradation. Cell Signal. 25:1498–1504. 2013. View Article : Google Scholar : PubMed/NCBI
31	Rao W, Li H, Song F, Zhang R, Yin Q, Wang Y, Xi Y and Ge H: OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells. Carcinogenesis. 35:1573–1581. 2014. View Article : Google Scholar : PubMed/NCBI